03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
22:53 , Jun 29, 2017 |  BC Innovations  |  Strategy

Lilly goes with the flow

In line with FDA’s push for companies to shift from batch processing to continuous manufacturing, Eli Lilly and Co. has published details of the first CGMP process for an API. The system shrinks a multi-room...
21:32 , Jun 8, 2017 |  BC Innovations  |  Translation in Brief

Damage potential

Although cancer drugs have proven effective in treating autoimmune diseases, their intolerable long-term toxicity has discouraged new players from exploring their potential. A group at University of Cincinnati has discovered a new combination that kills...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
02:41 , Oct 29, 2015 |  BC Extra  |  Clinical News

AZ's olaparib leads to responses in CRPC

Data published Wednesday in the New England Journal of Medicine showed olaparib ( AZD2281) from AstraZeneca plc (LSE:AZN; NYSE:AZN) led to a response in 33% of patients in the Phase II TOPARP-A study to...
08:00 , Dec 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma BRAF; checkpoint kinase 1 (Chk1; CHEK1); Chk2 (CHEK2); ataxia telangiectasia mutated (ATM); VEGF In vitro and...
08:00 , Feb 20, 2014 |  BC Innovations  |  Targets & Mechanisms

Preserving the oocyte reserve

A Cornell University team has shown how knocking out checkpoint kinase 2 can preserve fertility in mice.1 The results suggest that companies have an opportunity with this kinase, which is less pursued than the well-trodden cancer...
08:00 , Feb 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Infertility Checkpoint kinase 2 (Chk2; CHEK2) Mouse studies suggest inhibiting CHK2 could prevent premature ovarian failure...
07:00 , Jul 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma Checkpoint kinase 2 (CHEK2; CHK2); MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2) In vitro...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Clinical News

XL844: Development discontinued

Exelixis said it discontinued development of XL844, which was in Phase I testing, due to a pipeline reprioritization to focus resources on other programs. Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif.   Product: XL844   Business: Cancer...